Compare Boston Scientific Corporation (BSX) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Ecolab Inc. — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Ecolab Inc. trades at $269.19 (market cap $75.92B). The key difference: Boston Scientific Corporation and Ecolab Inc. are close in size by market cap, and Ecolab Inc. pays a 1.08% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ECL | |
|---|---|---|
Market Cap | $66.37B | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $308.35 |
52-Week Low | $42.63 | $245.73 |
Enterprise Value | $75.94B | $84.66B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
ECL trades at $271.85, down 0.9% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.43, implying significant upside. Recent financials show revenue growth to $16.08B in 2025 and a net income margin of 12.8%, though earnings have been mixed with a Q2 2026 estimate of $2.08 pending. The company's acquisition of CoolIT for $4.75B strengthens its AI cooling portfolio, positioning it for long-term growth in high-tech markets.
The outlook for ECL is positive, supported by strong analyst buy ratings (75.68%) and strategic expansions, but risks include execution of recent acquisitions and cost pressures. The stock's current valuation multiples, such as a P/E of 36.79, suggest premium pricing that requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
